All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): COVID-19 S-Trimer vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: SCB-2019
Highest Development Status: Phase I Product Type: Vaccine
Partner/Sponsor/Collaborator: CEPI
Deal Size: $328.0 million Upfront Cash: $69.5 million
Deal Type: Funding November 03, 2020
Details:
Funding will support development of Clover’s protein-based S-Trimer vaccine candidate through to licensure, including a global pivotal Phase 2/3 efficacy clinical study beginning before the end of 2020.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): COVID-19 S-Trimer vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: SCB-2019
Highest Development Status: Phase I Product Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 30, 2020
Details:
Clover is the second Chinese developer to apply for Phase 3 clinical trials in the Philippines following Sinovac Biotech, which is seeking to begin trials of its vaccine as early as next month.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): COVID-19 S-Trimer vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: SCB-2019
Highest Development Status: Phase I Product Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 25, 2020
Details:
Preclinical data show Clover’s protein-based adjuvanted COVID-19 vaccine candidate, S-Trimer, induces a strong neutralizing immune response in animals and protects nonhuman primates from SARS-CoV-2 challenge.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): JS016
Therapeutic Area: Infections and Infectious Diseases Product Name: JS016
Highest Development Status: Phase I Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 12, 2020
Details:
The study is a randomized, double-blind, placebo-controlled Phase I trial is intended to investigate the safety and tolerability of single dose JS016 intravenous injection (IV) in 40 healthy subjects.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): S-Trimer COVID vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase I Product Type: Vaccine
Partner/Sponsor/Collaborator: CEPI
Deal Size: Undisclosed Upfront Cash: $66.0 million
Deal Type: Funding July 08, 2020
Details:
Funding will support clinical development in parallel with scale-up of manufacturing capacity to potentially produce hundreds of millions of doses per year.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): COVID-19 S-Trimer vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: SCB-2019
Highest Development Status: Phase I Product Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 19, 2020
Details:
First participants have been dosed in the Phase 1 first-in-human study evaluating the company’s COVID-19 S-Trimer subunit vaccine candidate (SCB-2019), which is based on Clover’s proprietary Trimer-Tag© vaccine technology platform.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): JS016
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase I Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 07, 2020
Details:
JS016 is a recombinant fully human monoclonal neutralizing antibody that blocks the binding of the SARS-CoV-2 virus to the host cell surface receptor ACE2.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Adenovirus vector based SARS-CoV-2 vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase I Product Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 22, 2020
Details:
The vaccine candidate met the initial end points regarding adverse events and safety and provide evidence of immunogenicity against the target protein.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Ad5-nCoV
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase I Product Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 18, 2020
Details:
The Canadian Center for Vaccinology at Dalhousie University has received approval from Health Canada to conduct the country’s first clinical trials of a potential Covid-19 vaccine, Ad5-nCoV, developed under CanSino Biologics.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Ad5-nCoV
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase I Product Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 17, 2020
Details:
Joint developers submitted pre-investigational new drug review application for AD5-NCOV to regulatory authorities.
Drugs in Development
Market Place
Active Pharmaceutical Ingredients
Finished Drug Formulations
Price
Excipients
Services
Marketplace
